This content is in Portuguese.
This content is in Portuguese.
After approval, the clinical trial will be able to recruit and treat patients with B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin’s lymphoma at partner centers beginning in 2025.
This content is in Portuguese.
This content is in Portuguese.
This content is in Portuguese.
This content is in Portuguese.
This content is in Portuguese.
This content is in Portuguese.
This content is in Portuguese.
This content is in Portuguese.
This content is in Portuguese.